Can Beta-Lactam Allergy De-Labeling Strategies Safely Empower Geriatric Care?
Journal of Clinical Medicine · 15.05.2025 · 14 (10) · 3476
DOI: 10.3390/jcm14103476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.05.2025. Verfasst von Gal Goldhaber und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug allergies constitute a significant health concern among the elderly, with beta-lactam (BL) antibiotics among the most frequently implicated agents. Nevertheless, data regarding the safety and efficacy of BL allergy de-labeling in this population remain scarce. This study aimed to evaluate the safety and efficacy of BL allergy assessment in a cohort of geriatric patients carrying BL allergy labels.
Methods
We conducted a retrospective study, including patients aged >65 years who were referred for BL allergy evaluation at the Allergy Unit of Meir Medical Center. Patients underwent comprehensive anamnesis, skin testing, and, when indicated, oral challenge. Those successfully de-labeled were followed longitudinally to assess subsequent BL use and clinical outcomes.
Results
Between 2009 and 2019, 166 elderly patients with suspected BL allergies were evaluated. A BL allergy was ruled out in 145 patients (87.3%). Sixteen patients (9.6%) were diagnosed with immediate-type hypersensitivity, 2.4% of patients had severe delayed-type hypersensitivity reactions, and one patient (0.6%) had a benign rash. The evaluation process was safe, with no severe reactions occurring during oral challenges, and no patient required hospitalization or epinephrine administration. A long-term follow up was available for 106 patients; among them, 38 (35.8%) received subsequent treatment with the previously suspected BL agent, without any reports of immediate or severe delayed reactions.
Conclusions
Beta-lactam allergy de-labeling is safe and effective in the elderly and supports the critical role of allergy evaluation in this population. Enhanced awareness and implementation of de-labeling protocols in geriatric patients are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
- Geriatric Department, Meir Medical Center, Kfar Saba 4428163, Israel.
- Allergy and Clinical Immunology Unit, Meir Medical Center, Kfar Saba 4428163, Israel.
Zitieren
APA
Goldhaber, G., Confino-Cohen, R., Lachover-Roth, I., Cohen-Engler, A., Sity-Harel, S., & Rosman, Y. (2025). Can Beta-Lactam Allergy De-Labeling Strategies Safely Empower Geriatric Care?. Journal of Clinical Medicine, 14(10), 3476. https://doi.org/10.3390/jcm14103476
Vancouver
Goldhaber G, Confino-Cohen R, Lachover-Roth I, Cohen-Engler A, Sity-Harel S, Rosman Y. Can Beta-Lactam Allergy De-Labeling Strategies Safely Empower Geriatric Care?. Journal of Clinical Medicine. 2025;14(10):3476. doi:10.3390/jcm14103476
BibTeX
@article{Goldhaber2025,
author = {Goldhaber, Gal and Confino-Cohen, Ronit and Lachover-Roth, Idit and Cohen-Engler, Anat and Sity-Harel, Saray and Rosman, Yossi},
title = {Can Beta-Lactam Allergy De-Labeling Strategies Safely Empower Geriatric Care?},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {10},
pages = {3476},
doi = {10.3390/jcm14103476}
}
EUVIMED